Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab in Locally Advanced Nasopharyngeal Carcinoma
NCT04910347Phase 2Active, not recruiting
- Sponsor
- Yonsei University
- Start
- Feb 2022
- Primary completion
- Apr 2031
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab in nasopharyngeal carcinoma (NPC), sponsored by Yonsei University. Started Feb 2022; status: active, not recruiting.
02
Drugs
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT04910347.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04910347.